Physician profile
George E Munoz
NPI 1417989310
$147,261.96
in general payments reported to CMS, 2019-2025
29 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $8,435 · 2021: $11K · 2022: $42K · 2023: $32K · 2024: $16K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Travel and Lodging: $7,384 · Food and Beverage: $7,092 · Consulting Fee: $4,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,852.50 |
| Travel and Lodging | $7,383.88 |
| Food and Beverage | $7,091.78 |
| Consulting Fee | $4,965.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $136,513.60 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $2,545.68 | 2019-2024 | Tremfya |
| Abbvie INC. | $1,458.60 | 2019-2025 | |
| Amgen INC. | $1,232.26 | 2019-2025 | Krystexxa, Enbrel, Evenity |
| Horizon Therapeutics Plc | $1,061.00 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $733.11 | 2019-2025 | Benlysta |
| Genzyme Corporation | $683.64 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $408.03 | 2019-2025 | Orencia |
| Lilly USA, LLC | $356.91 | 2019-2023 | Taltz |
| Astrazeneca Pharmaceuticals Lp | $309.49 | 2021-2025 | Saphnelo |
| Alexion Pharmaceuticals, INC. | $287.28 | 2023-2024 | Strensiq |
| Pfizer INC. | $280.58 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $220.02 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $214.09 | 2020-2025 | Acthar |
| Alvogen INC | $184.56 | 2022-2025 | Teriparatide |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $177.58 | 2019-2023 | Tymlos |
| Depuy Synthes Sales INC. | $125.36 | 2022-2024 | Orthovisc |
| Aurinia Pharma U.S., INC. | $117.21 | 2021-2023 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.53 | 2024 | |
| Integra Lifesciences Corporation | $40.11 | 2023 | Integra, Surgimend, Omnigraft |
| Pacira Therapeutics, INC. | $33.92 | 2019 | |
| Fresenius Kabi USA, LLC | $33.55 | 2023 | |
| Mallinckrodt Enterprises LLC | $33.53 | 2019 | |
| Ani Pharmaceuticals, INC. | $32.37 | 2025 | Purified Cortrophin Gel |
| Medexus Pharma, INC. | $31.58 | 2019-2020 | |
| Sobi, INC | $21.77 | 2025 | |
| Ferring Pharmaceuticals INC. | $21.01 | 2019 | |
| Organon LLC | $18.12 | 2021 | |
| Cardinal Health 108 LLC | $13.47 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Munoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.